Fig. 7: Combinational targeting of EZH2 and ADAR1 reaches a synergistic effect in PCa treatment.

Western blot to detect EZH2, SUZ12, EED, ADAR1 and H3K27me3 levels in C4-2 cells treated with MS8815 (a) or EPZ6438 (b) at various dosages as indicated. C4-2 cells treated with 5 μM of MS177 was also detected as reference. c Growth curve of C4-2 cells treated with MS8815, MS177 or EPZ6438 at different concentrations to measure the IC₅₀ value. Data represent the mean ± SD from n = 6 biologically independent experiments. d–f C4-2 cells stably expressing Dox-inducible control or ADAR1 shRNA were injected subcutaneously into SCID mice, followed by treatment using vehicle, MS8815 or EPZ6438. Tumor volume was measured by caliper twice a week and plotted in (d). At the end point of measurement, tumors were harvested, weighted (e) and pictured (f). Data represent Mean ± SD from n = 8 mice in each group. g, h The LuCaP 35CR PDX tumors were implanted subcutaneously into SCID mice, followed by delivery of nanoparticles carrying siRNAs. Tumor volume was measured by caliper twice a week and plotted in (g). At the end point of measurement, tumors were harvested and weighted (h). Data represent Mean ± SD from n = 10 mice in each group. Statistical significance was assessed using two-sided student’s t test unless otherwise stated. Source data are provided as a Source Data file.